The Company generated total net revenues of
Announced positive topline results from two Phase 3 clinical trials evaluating DFD-29 (minocycline hydrochloride modified release capsules, 40mg); both trials achieved the co-primary and all secondary endpoints over placebo and the current standard of care Oracea® (doxycycline, 40mg) with no significant safety issues
The Company plans to submit a New Drug Application to FDA for DFD-29 in the second half of 2023
Company to hold conference call today at
Journey Medical’s Vice President of R&D, Srinivas Sidgiddi, M.D., who has led this development program from inception, added, “Both Phase 3 trials achieved their co-primary and all secondary endpoints, and DFD-29 demonstrated statistical superiority over both placebo and the current standard of care, Oracea 40 mg. These results demonstrate the potential for DFD-29, if approved, to be the best-in-class systemic therapy in the treatment of rosacea. DFD-29 has the potential to address the large unmet need for safe and efficacious therapies that address the inflammatory lesions and the redness of rosacea.”
Financial Results:
- Total net revenues in the second quarter of 2023 were
$17.2 million , a decrease of$1.1 million compared to the second quarter of 2022. The decrease is primarily due to lower unit volumes from the Company’s legacy products, Targadox®, Ximino® and Exelderm® substantially driven by continued generic competition for Targadox. The results were offset by an increase in net product revenues from the Company’s four core products, Qbrexza®, Accutane®, Amzeeq® and Zilxi® due to increased unit volumes as a result of the Company’s focused sales and marketing emphasis on these products, which lead to 19% growth year-over-year and now reflect approximately 92%, or$15.6 million , of the Company’s total net product revenue for second quarter of 2023. - Selling, general and administrative expenses (“SG&A”) decreased by
$3.0 million , or 20%, to$12.1 million for the second quarter 2023, from$15.2 million for the second quarter 2022. The decrease is mainly attributable to the Company’s expense reduction efforts, primarily in sales and marketing and other SG&A areas. During Q4 2022, the Company implemented a cost reduction initiative designed to improve operational efficiencies, optimize expenses and reduce overall costs. The initiative is intended to reduce SG&A expenses to better align costs with revenues being generated. In connection with the cost reduction initiative, the Company pivoted to focus on its four core products, allowing it to minimize overall headcount including its sales force along with implemented marketing and other cost cuts. The impact of the cost reduction initiatives is expected to result in a reduction of greater than$12.0 million of annual SG&A expenses. - Research and Development (“R&D”) expenses decreased by
$0.8 million , or 32%, to$1.8 million for the second quarter 2023, from$2.6 million for second quarter 2022. The decrease is related to lower clinical trial expenses, as the two Phase 3 studies have concluded. - The Company recorded a non-cash loss on the impairment of the Ximino intangible asset of
$3.1 million in the second quarter 2023. During the six months endedJune 30, 2023 , the Company experienced lower net product revenues and gross profit levels for its Ximino product. - GAAP net loss was
$8.4 million , or$0.46 per share basic and diluted, for the second quarter of 2023, compared to a GAAP net loss of$10.1 million , or$0.57 per share basic and diluted, for the first quarter of 2023 and$7.5 million , or$0.43 per share basic and diluted, for the second quarter of 2022. - The Company’s non-GAAP results in the table below reflect Adjusted EBITDA of
$(0.6 million) , or$(0.04) per share basic and diluted, for the second quarter of 2023, compared to Adjusted EBITDA of$(5.3 million) , or$(0.30) per share basic and diluted, for the first quarter of 2023 and Adjusted EBITDA of $(2.6 million), or$(0.15) per share basic and diluted for the second quarter of 2022. Adjusted EBITDA, Adjusted EBITDA per share basic and diluted are non-GAAP financial measures, each of which are reconciled to the most directly comparable financial measures calculated in accordance with GAAP below under “Use of Non-GAAP Measures.” - At
June 30, 2023 , the Company had$17.0 million in cash and cash equivalents including$8.75 million of restricted cash as compared to$26.1 million of cash and cash equivalents and$8.75 million of restricted cash atMarch 31, 2023 and$32.0 million in cash and cash equivalents as ofDecember 31, 2022 . The decrease in cash from the first quarter was primarily a result of$13.0 million in repayments on our EWB debt facility. Subsequently, inJuly 2023 , the Company voluntarily paid-off the entire$10.0 million outstanding EWB term loan. The Company no longer has any outstanding bank debt.
Recent Corporate Highlights:
- In
July 2023 ,Journey Medical announced positive topline data from its two DFD-29 Phase 3 clinical trials for the treatment of PPR. The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues. DFD-29 demonstrated statistical superiority over both the standard of care Oracea capsules and placebo for Investigator’s Global Assessment treatment success and the reduction in the total inflammatory lesion count in both studies.Journey Medical plans to file an NDA to theU.S. Food and Drug Administration for DFD-29 in the second half of 2023 and expects potential approval from the FDA in the second half of 2024.
Summary Topline Results from MVOR-1 and MVOR-2
MVOR-1 | MVOR-2 | |||
IGA Success at Week 16 | Inflammatory Lesion Change at Week 16 | IGA Success at Week 16 | Inflammatory Lesion Change at Week 16 | |
DFD-29 (40 mg) | 65.0% | -21.3 | 60.1% | -18.4 |
Oracea (40 mg) | 46.1% | -15.9 | 31.4% | -14.9 |
Placebo | 31.2% | -12.2 | 26.8% | -11.1 |
P-value: DFD-29 versus Oracea | P=0.014 | P<0.001 | P<0.001 | P<0.001 |
P-value: DFD-29 versus Placebo | P<0.001 | P<0.001 | P<0.001 | P<0.001 |
- In
June 2023 ,Journey Medical announced positive Phase 1 clinical trial data assessing the impact of DFD-29 on the microbial flora of healthy adults. Results indicated that DFD-29 can be safely used for up to 16 weeks with no significant risk of microbiota suppression or development of resistance.
Conference Call and Webcast Information
To listen to the conference call, interested parties within the
A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the meeting.
About
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “the Company”, “we”, “us” and “our” may refer to
Company Contact:
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
Unaudited Condensed Consolidated Balance Sheets | |||||||
(Dollars in thousands except for share and per share amounts) | |||||||
2023 | 2022 | ||||||
ASSETS | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 8,230 | $ | 32,003 | |||
Accounts receivable, net of reserves | 16,737 | 28,208 | |||||
Inventory | 12,166 | 14,159 | |||||
Prepaid expenses and other current assets | 1,796 | 3,309 | |||||
Restricted cash | 8,750 | - | |||||
Total current assets | 47,679 | 77,679 | |||||
Intangible assets, net | 21,916 | 27,197 | |||||
Operating lease right-of-use asset, net | 146 | 189 | |||||
Other assets | 6 | 95 | |||||
Total assets | $ | 69,747 | $ | 105,160 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current liabilities | |||||||
Accounts payable | $ | 31,773 | $ | 36,570 | |||
Due to related party | 603 | 413 | |||||
Accrued expenses | 23,329 | 19,388 | |||||
Accrued interest | 83 | 160 | |||||
Income taxes payable | 35 | 35 | |||||
Line of credit | - | 2,948 | |||||
Term loan, short-term (net of discount of | 9,942 | - | |||||
Deferred cash payment (net of discount of | - | 4,991 | |||||
Installment payments – licenses, short-term | 2,333 | 2,244 | |||||
Operating lease liability, short-term | 95 | 83 | |||||
Total current liabilities | 68,193 | 66,832 | |||||
Term loan, long-term (net of debt discount of | - | 19,826 | |||||
Installment payments – licenses, long-term | 1,490 | 1,412 | |||||
Operating lease liability, long-term | 59 | 108 | |||||
Total liabilities | 69,742 | 88,178 | |||||
Stockholders' equity | |||||||
Common stock, | 1 | 1 | |||||
Common stock - Class A, | 1 | 1 | |||||
Additional paid-in capital | 87,004 | 85,482 | |||||
Accumulated deficit | (87,001 | ) | (68,502 | ) | |||
Total stockholders' equity | 5 | 16,982 | |||||
Total liabilities and stockholders' equity | $ | 69,747 | $ | 105,160 | |||
Unaudited Condensed Consolidated Statements of Operations | |||||||||||||||
(Dollars in thousands except for share and per share amounts) | |||||||||||||||
Three-Month Periods Ended | Six-Month Periods Ended | ||||||||||||||
| |||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
Revenue: | | | | | | | | | | | |||||
Product revenue, net | $ | 16,961 | | $ | 18,235 | $ | 29,126 | | $ | 39,031 | |||||
Other revenue | 211 | 56 | 259 | 2,556 | |||||||||||
Total revenue | 17,172 | 18,291 | 29,385 | 41,587 | |||||||||||
Operating expenses | | | | | | | | | | | |||||
Cost of goods sold – product revenue | | 7,767 | | | 7,633 | | 14,216 | | | 15,836 | |||||
Research and development | | 1,774 | | | 2,609 | | 3,807 | | | 3,875 | |||||
Selling, general and administrative | | 12,141 | | | 15,191 | | 25,433 | | | 29,906 | |||||
Loss on impairment of intangible assets | 3,143 | - | 3,143 | - | |||||||||||
Total operating expenses | | 24,825 | | | 25,433 | | 46,599 | | | 49,617 | |||||
Loss from operations | | (7,653 | ) | | | (7,142 | ) | | (17,214 | ) | | | (8,030 | ) | |
Other expense (income) | |||||||||||||||
Interest income | (79 | ) | | | (4 | ) | (201 | ) | (7 | ) | |||||
Interest expense | | 756 | | | 454 | 1,406 | 843 | ||||||||
Foreign exchange transaction losses | 33 | - | 80 | - | |||||||||||
Total other expense (income) | | 710 | | | 450 | | 1,285 | | | 836 | |||||
Loss before income taxes | | (8,363 | ) | | | (7,592 | ) | | (18,499 | ) | | | (8,866 | ) | |
Income tax (benefit) expense | - | (64 | ) | - | 40 | ||||||||||
Net Loss | $ | (8,363 | ) | | $ | (7,528 | ) | $ | (18,499 | ) | | $ | (8,906 | ) | |
Net loss per common share: | |||||||||||||||
Basic and diluted | $ | (0.46 | ) | | $ | (0.43 | ) | $ | (1.03 | ) | | $ | (0.51 | ) | |
Weighted average number of common shares: | |||||||||||||||
Basic and diluted | 18,005,055 | 17,455,894 | 17,906,671 | 17,386,538 | |||||||||||
Use of Non-GAAP Measures:
In addition to the GAAP financial measures, the Company has, in this press release, included certain non-GAAP measurements, including Adjusted EBITDA, Adjusted EBITDA per share basic and Adjusted EBITDA per share diluted. We define Adjusted EBITDA as net income (loss) excluding interest, taxes and depreciation, less certain other non-cash and infrequent items not considered to be normal, recurring operating expenses, including, share-based compensation expense, amortization and impairment of acquired intangible assets, inventory step-ups from the purchases of intangibles assets and products, severance, non-core research and development expense and foreign exchange transaction losses. In particular, we exclude the following matters for the reasons more fully described below:
- Share-Based Compensation Expense: We exclude share-based compensation from our adjusted financial results because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued.
Non-core and Short-term Research and Development Expense: We exclude research and development costs incurred in connection with our DFD-29 product candidate, which is the only product in our portfolio not currently approved for marketing and sale, because we do not consider such costs to be normal, recurring operating expenses that are core to our long-term strategy. Instead, our long-term strategy is focused on the marketing and sale of acquired and/or licensed FDA-approved dermatological products.- Amortization and impairments of Acquired Intangible assets: We exclude the impact of certain amounts recorded in connection with the acquisitions of intangible assets that are either non-cash or not normal, recurring operating expenses due to their nature, variability of amounts, and lack of predictability as to occurrence and/or timing. These amounts may include non-cash items such as the amortization of acquired intangible assets, impairments and amortization of step-ups of acquisition accounting adjustments to inventories.
Adjusted EBITDA per share basic and Adjusted EBITDA per share diluted are determined by dividing the resulting Adjusted EBITDA by the number of shares outstanding on an actual and fully diluted basis.
Management believes use of these non-GAAP measures provide meaningful supplemental information regarding the Company’s performance because (i) it allows for greater transparency with respect to key measures used by management in its financial and operational decision-making, (ii) it excludes the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the Company’s core operating performance and that may obscure trends in the Company’s core operating performance and (iii) it is used by institutional investors and the analyst community to help analyze the Company's results. However, Adjusted EBITDA, Adjusted EBITDA per share basic, Adjusted EBITDA per share diluted and any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non-GAAP financial measures used by the Company and the manner in which they are calculated may differ from the non-GAAP financial measures or the calculations of the same non-GAAP financial measures used by other companies, including the Company’s competitors.
The table below provides a reconciliation from GAAP to non-GAAP measures:
Reconciliation of GAAP to Non-GAAP Adjusted EBITDA | ||||||||||||||||||||
($ in thousands except for share and per share amounts) | ||||||||||||||||||||
Three-month period ended | Three-month periods ended | Six-month periods ended | ||||||||||||||||||
2023 | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
GAAP Net Loss | $ | (10,136 | ) | $ | (8,363 | ) | $ | (7,528 | ) | $ | (18,499 | ) | $ | (8,906 | ) | |||||
EBITDA: | ||||||||||||||||||||
Interest | 528 | 677 | 450 | 1,205 | 836 | |||||||||||||||
Taxes | - | - | (64 | ) | - | 40 | ||||||||||||||
Depreciation | - | - | - | - | - | |||||||||||||||
Amortization of acquired intangible assets | 1,069 | 1,069 | 1,017 | 2,138 | 2,034 | |||||||||||||||
EBITDA | (8,539 | ) | (6,617 | ) | (6,125 | ) | (15,156 | ) | (5,996 | ) | ||||||||||
Non-GAAP Adjusted EBITDA: | ||||||||||||||||||||
Share-based compensation | 646 | 873 | 774 | 1,519 | 1,547 | |||||||||||||||
Loss on impairment of intangible assets | - | 3,143 | - | 3,143 | - | |||||||||||||||
Inventory step-up expense | - | - | 171 | - | 311 | |||||||||||||||
Non-core & short-term R&D | 1,999 | 1,744 | 2,609 | 3,743 | 3,875 | |||||||||||||||
Foreign exchange transaction losses | 47 | 33 | - | 80 | - | |||||||||||||||
Severance | 526 | 185 | - | 711 | - | |||||||||||||||
Non-GAAP Adjusted EBITDA | $ | (5,321 | ) | $ | (639 | ) | $ | (2,571 | ) | $ | (5,960 | ) | $ | (263 | ) | |||||
Net loss per common share Basic and diluted : | ||||||||||||||||||||
GAAP Net loss | $ | (0.57 | ) | $ | (0.46 | ) | $ | (0.43 | ) | $ | (1.03 | ) | $ | (0.51 | ) | |||||
Non-GAAP Net loss | $ | (0.30 | ) | $ | (0.04 | ) | $ | (0.15 | ) | $ | (0.33 | ) | $ | (0.02 | ) | |||||
Weighted average number of common shares Basic and diluted : | 17,807,194 | 18,005,055 | 17,455,894 | 17,906,671 | 17,386,538 |
Source:
2023 GlobeNewswire, Inc., source